Mandate

Vinge advises Impilo on the establishment of Impilo Healthcare

July 01, 2025 Private Funds

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Healthcare. The fund will have EUR 320m in commitments.

Impilo is a Nordic investment company focused solely on investments in lower-mid market Nordic healthcare companies across the pharmaceuticals, MedTech, specialist pharma services and other healthcare and related services industries. Impilo has a well-diversified portfolio of healthcare investments and manages approximately EUR 2 billion of capital from leading international investors.

Vinges team consisted of Nils UnckelAnton Sjökvist, Viktoria Wnuk and Isabelle Asserståhl.

Related

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson to Citira, a European tire management provider and portfolio company of Norvestor. Headquartered in Stockholm, Malte Månson is an independent service and repair provider for commercial vehicles and operates a network of 28 service workshop locations across Sweden, authorized by brands such as MAN, DAF, IVECO, Mercedes-Benz, Setra, VDL and EVO. Malte Månson has an annual revenue of SEK 800 million and employs over 300 full-time professionals.
June 08, 2026

Vinge advises InArea on entering into a SEK 450 million credit agreement with SEB

InArea's new facilities agreement comprises a term loan and a revolving credit facility, replacing the company's existing facilities. The facilities agreement also includes an option to increase the lending framework through an incremental facility of up to SEK 200 million.
June 03, 2026

Vinge has advised the arrangers in connection with St1 Biokraft’s EUR 260 million financing

Vinge has advised the arrangers, ING Bank N.V., ABN AMRO Bank N.V., DNB Bank ASA, Nordea Bank Abp, OP Corporate Bank plc, Coöperatieve Rabobank U.A., SpareBank 1 Sør-Norge ASA and Swedbank AB, in connection with St1 Biokraft AB’s EUR 260 million financing.
June 03, 2026